as on December 6, 2025 at 2:29 am IST
Day's Low
Day's High
1.89%
Downside
4.61%
Upside
52 Week's Low
52 Week's High
84.43%
Downside
9.26%
Upside
Check Arrowhead Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$8.5B
EPS (TTM)
-0.0336
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.10%
PE Ratio (TTM)
-5.56
Industry PE ratio
9.564035087719299
PEG Ratio
-1.32
EBITDA
122.3M
Revenue (TTM)
829.4M
Profit Margin
-0.20%
Return On Equity TTM
8.67%
Track how Arrowhead Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Arrowhead Pharmaceuticals, Inc. in the last 5 years
Lowest (-72.52x)
March 31, 2021
Today (-5.56x)
December 6, 2025
Industry (9.56x)
December 6, 2025
Highest (-3.99x)
December 31, 2024
Today’s Price to Earnings Ratio: -5.56x
Compare market cap, revenue, PE, and other key metrics of Arrowhead Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $8.5B | -5.9% | -5.56 | -0.20% | |
| BUY | $43.5B | 408.22% | -16.34 | -264.83% | |
| BUY | $61.5B | 253.6% | 1661.93 | 1.36% | |
| BUY | $117.3B | 99.49% | 32.16 | 31.35% | |
| BUY | $76.6B | 45.87% | 17.31 | 32.13% |
The Arrowhead Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Arrowhead Pharmaceuticals, Inc. investment value today
Current value as on today
₹2,66,440
Returns
₹1,66,440
(+166.44%)
Returns from Arrowhead Pharmaceuticals, Inc. Stock
₹1,60,271 (+160.27%)
Dollar Returns*
₹6,168 (+6.17%)
Based on 20 analysts
75.00%
Buy
25.00%
Hold
0.00%
Sell
Based on 20 analysts, 75% of analysts recommend a 'BUY' rating for Arrowhead Pharmaceuticals, Inc.. Average target price of $57.67
Get share price movements and forecasts by analysts on Arrowhead Pharmaceuticals, Inc..
What analysts predicted
-6.55%DOWNSIDE
Target Price
$57.67
Current Price
$61.45
Analyzed by
20 Analysts
Target
$57.67
Arrowhead Pharmaceuticals, Inc. target price $57.67, a slight downside of -6.55% compared to current price of $61.45. According to 20 analysts rating.
Investment in Arrowhead Pharmaceuticals, Inc. Shares on INDmoney has grown by 125.58% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:125.58% versus previous 30 day period
Search interest for Arrowhead Pharmaceuticals, Inc. Stock has increased by 607% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:607% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 25 November
Tue, 11:38 PM
-Sarepta triggers a $200 million milestone payment to Arrowhead Pharmaceuticals as part of a licensing deal.
Wed, 02:48 AM
-Arrowhead Pharmaceuticals releases its 10-K report, showcasing improved financial performance and strategic initiatives in RNAi therapeutics.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, ARWR stock has moved up by 16.6%
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 27.76M → 256.47M (in $), with an average increase of 89.2% per quarter
Profit Spike
![]()
Netprofit is up for the last 2 quarters, -175.24M → -23.75M (in $), with an average increase of 637.9% per quarter
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 170.6% return, outperforming this stock by 10.4%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 977.7% return, outperforming this stock by 890.7%
| Organisation | Arrowhead Pharmaceuticals, Inc. |
| Headquarters | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
| Industry | Health Technology |
| CEO | Dr. Christopher R. Anzalone Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
Mr. Daniel J. Apel | Chief Financial Officer |
Dr. Mark Seefeld | Head of Toxicology & VP |
Aaron Tan | Head of Tax |
Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President |
Mr. Patrick O'Brien J.D., PharmD | COO, General Counsel & Secretary |
Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D |
Dr. Vincent Anzalone CFA | Head of Investor Relations & VP |
Mr. Howard Lovy | Director of Communications |
Dr. Bruce D. Given M.D. | Chief Medical Scientist |
Arrowhead Pharmaceuticals, Inc. share price today is $61.45 as on at the close of the market. Arrowhead Pharmaceuticals, Inc. share today touched a day high of $64.28 and a low of $60.29.
Arrowhead Pharmaceuticals, Inc. share touched a 52 week high of $67.14 on and a 52 week low of $9.57 on . Arrowhead Pharmaceuticals, Inc. stock price today i.e. is closed at $61.45,which is 8.47% down from its 52 week high and 542.11% up from its 52 week low.
Arrowhead Pharmaceuticals, Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Arrowhead Pharmaceuticals, Inc. (ARWR) shares with as little as ₹89.896 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹898.96 in Arrowhead Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Arrowhead Pharmaceuticals, Inc. share’s latest price of $61.45 as on December 6, 2025 at 2:29 am IST, you will get 0.1627 shares of Arrowhead Pharmaceuticals, Inc.. Learn more about
fractional shares .
Arrowhead Pharmaceuticals, Inc. stock has given -5.9% share price returns and 22.22% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?